Business Wire

MI-LINEAGE-LOGISTICS

2.11.2021 08:02:13 CET | Business Wire | Pressemeddelelse

Del
Lineage Logistics gennemfører opkøb af Claus Sørensens køleopbevaringsafdeling

Lineage Logistics, LLC (”Lineage” eller ”selskabet”), en førende global udbyder af temperaturstyret industriel REIT og logistikløsninger, meddelte i dag, at de har afsluttet opkøbet af køleopbevaringsafdelingen i Claus Sørensen Gruppen, en anerkendt operatør inden for køleopbevaring i Danmark.

Købet blev først annonceret den 15. juni 2021.

Udvidelsen i Danmark er en afgørende del af Lineages vækstplaner i Norden. Opkøbet giver Lineages globale rækkevidde en vigtig forbindelse til Danmark, som er ved at udvikle sig til et førende europæisk midtpunkt inden for den globale køleopbevaringsforsyningskæde, med luftfragt og søfartsinfrastruktur i verdensklasse.

Virksomhedens nuværende tilstedeværelse i Danmark forstærkes igennem Lineages opkøb af Claus Sørensen og tilføjer betydelige volumener på strategiske lokationer nær danske havne og centre for fødevareproduktion.

”Claus Sørensens relationer og tilgang til forretning vil sætte skub i vores vækstplaner i Norden”, siger Harld Peters, Senior Vice President for Europa hos Lineage. ”Vi ser frem til at arbejde sammen med dem for at betjene vores kunder i hele Europa”.

Claus Sørensen, som har hovedkvarter i Esbjerg, har en kapacitet på næsten en million kubikmeter og 200.000 pallepositioner fordelt på ni lagre og mere end 250 teammedlemmer. Med opkøbet og færdiggørelsen af igangværende byggeri i regionen, vil Lineages samlede fodaftryk i Danmark omfatte 17 lokationer og næsten 300.000 pallepositioner.

Claus Sørensen leverer køleopbevaring til kød og fjerkræ, brød, is, færdigretter, frugt og grønt og mejeriprodukter. Ud over opbevaring leverer virksomheden blæsefrysning, kvalitetskontrol, ordresammensætning og pakning, isproduktion, told og distribution til detailhandel og catering. Claus Sørensen kan fryse 1.800 tons produkter om dagen. Claus Sørensen er som et vigtigt led i den danske fødevare- og drikkevareforsyningskæde gået sammen med sine kunder for at forbedre deres forsyningskædeoperationer, opnå maksimal energiudnyttelse og beskytte miljøet.

”Lineage er stærkt engagerede i både innovation og service, hvilket passer perfekt til vores mangeårige forpligtelse til at være vores kunders foretrukne partner”, siger Jesper Toft Mathiasen, CEO hos Claus Sørensen. ”Vi glæder os til at blive en del af en virksomhed, der deler vores værdier, og til at slå os sammen med Lineages team i regionen for at transformere vores kunders forsyningskæde og hjælpe dem med at få deres forretninger til at vokse”.

Lineage Logistics kom ind på det nordiske marked i 2020. Siden da har virksomheden opkøbt Lundsøe Køl & Frys A/S med kølelagerfaciliteter i Nordjylland og Aarhus, Super Frost Sjælland ApS og Coldstar ApS, udover opkøbet af Claus Sørensen.

Om Lineage Logistics: Lineage Logistics er en førende udbyder af temperaturstyret industriel REIT og logistikløsninger. Firmaet har et globalt netværk på over 400 strategisk placerede faciliteter med en samlet kapacitet på over 60 millioner kubikmeter, der spænder over 19 lande fra Nordamerika, Europa og Asien-Stillehavsområdet. Lineages ekspertise indenfor brugsklare løsninger, deres uovertrufne netværk af fast ejendom og udvikling af innovativ teknologi er med til at øge distributionseffektiviteten, fremme bæredygtighed, minimere spild i forsyningskæden og, vigtigst af alt, som visionær partner med Feeding America, være med til at brødføde verden. Som en anerkendelse af firmaets initiativer inden for innovation og bæredygtighed opnåede Lineage at blive nr. 17 på CNBC Disruptor 50-listen i 2021, nr. 1 som bedste datavidenskabsvirksomhed og samlet nr. 23 på Fast Companys liste over verdens mest innovative virksomheder i 2019, udover at være med på Fortunes Change The World-liste i 2020. (www.lineagelogistics.com )

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye